The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

Standard COPD treatment includes older medications ... Dupixent is an antibody designed to block the IL-3 and IL-4 pathways. The drug currently has approvals in seven indications, most recently ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

Lead investigator Tao Wang says, "The prognosis for individuals with COPD complicated by cor pulmonale is generally poor, and the existing treatment ... identified that pathways involving ...